The treatment effect of LNG-IUS combined with COC on main symptoms and irregular vaginal bleeding

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053110

Enrollment

Unknown

Registered

2021-11-11

Start date

2021-11-11

Completion date

Unknown

Last updated

2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis

Interventions

A group:Levonorgestrel intrauterine birth control system

B group:Levonorgestrel intrauterine birth control system+Baogong hemostatic granules

C group:Levonorgestrel intrauterine birth control system+Yousemin

D group:Levonorgestrel intrauterine birth control system+Youseyue

Eligibility

Sex/Gender

Female

Age

No minimum to 45 Years

Inclusion criteria

Inclusion criteria: 1.The patient should poss a certain level of education, and have good language understanding and expression skills; 2.The patients intelligence is in line with ordinary people's level, and can assist in completing the questionnaire survey and collecting clinical data alone; 3.Meet with the clinical criteria for adenomyosis in the "Guidelines for the Diagnosis and Treatment of Endometriosis"; 4.These patients have been diagnosed by CA125 detection, B-ultrasonic examination, MRI, hysterosalpingography, myometrial acupuncture biopsy or some other related laboratory examination; 5.Patients with the symptoms of dysmenorrhea; 6.Comply with the therapeutic indications of LNG-IUS intrauterine device.

Exclusion criteria

Exclusion criteria: 1.Patients had a history of drug allergy about drospirenone ethoestradiol tablets or Baogong hemostatic granules; 2.Patients with a history of mental illness or mental disorders; 3.Patients with other diseases that can cause abdominal pain, dysmenorrhea, and vaginal bleeding; 4.Patients with severe organic diseases; 5.Patients who suffer from other related gynecological diseases such as uterus, ovaries, and cervix; 6.Patients with abnormal liver, kidney, and coagulation function; 7.Patients aged > 45 years; 8.Patients who have contraindications to use the intrauterine contraceptive device.

Design outcomes

Primary

Measure	Time frame
Irregular vaginal bleeding rate;Visual analogue pain scale;Menstrual bleeding chart;Endometriosis Quality of Life Scale;Decyclization rate, ring down condition;	—

Countries

China

Contacts

Public ContactWang Guoyun

Qilu Hospital of Shandong University

202120800@mail.sdu.edu.cn+86 18560081729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026